Heron Therapeuti (HRTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.31 (-1.90%), Market cap $0.16B, 52-week low–high $0.75 ~ $2.23.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a
Financial statements, price targets, institutional (13F) holdings and related news for Heron Therapeuti are updated in real time on BlackAll Trade.
Heron Therapeuti trades at $0.31 (-1.90%). Real-time quotes and charts are available on BlackAll Trade.
Heron Therapeuti has a market cap of about $0.16B.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its propr